Tandem Diabetes Care Announces Proposed Private Placement of Convertible Notes

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today that it intends to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of its Convertible Senior Notes due 2032 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “S.

Business Wire • Feb 23, 2026

Tandem Diabetes Care: Strong Q4 Execution Amid A PayGo Transition

Tandem Diabetes Care, Inc. delivered strong Q4 '25 results, with revenue and gross margin beats driving a 32% stock surge. TNDM's shift to a pay-as-you-go model will temporarily compress reported revenue but should enable smoother, recurring income and improved long-term economics.

Seeking Alpha • Feb 23, 2026

Tandem Diabetes Care Analysts Boost Their Forecasts After Upbeat Q4 Results

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) reported better-than-expected fourth-quarter financial results on Thursday.

Benzinga • Feb 20, 2026

Tandem Diabetes Shares Rise 33% On Earnings Beat, Margin Expansion, Growth Outlook

The stock is moving higher as the broader market is experiencing positive momentum, with the Nasdaq up 0.62% today, contributing to the bullish sentiment.

Benzinga • Feb 20, 2026

Why Tandem Diabetes Care Stock Popped Today

Tandem saw robust demand for its insulin pumps in the fourth quarter. Management expects further shipment growth in 2026.

The Motley Fool • Feb 21, 2026

Tandem Diabetes Care, Inc. (TNDM) Q4 2025 Earnings Call Transcript

Tandem Diabetes Care, Inc. (TNDM) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 20, 2026

TNDM Q4 Earnings & Revenues Beat Estimates, Gross Margin & Stock Up

Tandem Diabetes tops Q4 estimates with narrower loss, 15% revenue jump and wider gross margin, sending shares up 6.7% after hours.

Zacks Investment Research • Feb 20, 2026

Tandem Diabetes Care Announces Fourth Quarter and Full Year 2025 Financial Results and 2026 Financial Guidance

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter and fiscal year ended December 31, 2025 and provided its financial guidance for the year ending December 31, 2026. Fourth Quarter 2025 Financial and Strategic Highlights Achieved record quarterly sales: Worldwide sales of $290.4 million United States sales of $210.5 million Worldwide pump shipments of 38,000 United.

Business Wire • Feb 19, 2026

Tandem Diabetes Care, Inc. (TNDM) Reports Q4 Loss, Tops Revenue Estimates

Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.44 per share a year ago.

Zacks Investment Research • Feb 19, 2026

Tandem Diabetes Care (TNDM) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • Feb 20, 2026